Oruka Therapeutics
Menlo Park, California, United States · Biotechnology, Healthcare, Health Care
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka's mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as one or twice a year. Oruka is advancing a pr
Key facts
- Headquarters
- Menlo Park, California, United States
- Employees
- Unknown
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (ORKA)
- Website
- arcabiopharma.com
- Company page
Recent activity at Oruka Therapeutics
- : Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
- : SEC 8-K (5.02):
- : SEC 8-K (8.01): On May 29, 2026, Oruka Therapeutics, Inc. entered into the First Amendment to the IL-23 License Agreement with Paragon Therapeutics, Inc. The Amendment expands the definition of 'Field' to include all therapeutic uses for inflammatory bowel disease, with specific dosing restrictions for clinical trials not allowing treatment until June 1, 2028, and complete monotherapy restrictions until June 1, 2030. This modification is significant as it broadens potential applications for ORKA-001, and allows for a more robust development strategy while imposing restrictions that impact future clinical activities. Additionally, if a material transaction occurs affecting control, the restrictions will be lifted after June 1, 2028.
- : SEC 8-K (8.01): On April 28, 2026, the Company entered into an Underwriting Agreement with several prominent investment firms, including Leerink Partners LLC and Goldman Sachs & Co. LLC, for the offering and sale of 9,660,000 shares of common stock at a public price of $72.50 per share. The Underwriters have an option to purchase an additional 1,449,000 shares within 30 days. The offering was completed on April 30, 2026, indicating a strategic move to raise significant capital. The agreement includes customary representations and indemnification provisions for the Underwriters concerning certain liabilities under the Securities Act.
- : SEC 8-K (8.01): On April 27, 2026, Oruka announced the results from its Phase 2a EVERLAST-A clinical trial of ORKA-001 for patients with moderate-to-severe psoriasis (PsO). The trial involved 84 patients, with 63.5% achieving complete skin clearance (PASI 100) at Week 16, significantly higher than the 4.8% in the placebo group (p < 0.0001). Key secondary endpoints were also met, indicating favorable efficacy and safety profiles. The trial is ongoing, and further data regarding long-term efficacy and safety will be available in the second half of 2026.
- : SEC 8-K (5.02): On December 11, 2025, Cameron Turtle resigned from the Board of Directors of Oruka Therapeutics, Inc. The resignation was not due to any disagreement or removal for cause. On the same day, Christopher Martin was appointed as a Class II director with a term extending to the 2026 annual meeting, and he was also appointed as Chair of the Compensation Committee and a member of the Audit Committee. Mr. Martin brings extensive experience from Verona Pharma, including leadership roles and a significant background in commercial strategy for product launches. The Board confirmed Mr. Martin’s independence as per Nasdaq standards, and there are no arrangements that influenced his selection as director.
- : SEC 8-K (5.02): On December 11, 2025, Cameron Turtle resigned from the Board of Directors of Oruka Therapeutics, Inc. This resignation was not due to any disagreement regarding the company's operations or policies. In conjunction with this change, the Board appointed Christopher Martin as a Class II director, who will serve until the 2026 annual meeting of stockholders. In addition to this role, Mr. Martin has been appointed as the Chair of the Compensation Committee and a member of the Audit Committee, suggesting a strategic effort to enhance the company's governance and oversight.
- : Oruka Therapeutics raised $200 million in a private placement to support its operations and growth.
- : ARCA biopharma, Inc.
Oruka Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2024 | Post-IPO Equity | $200.0M |
| Jun 2015 | Venture | $51.7M |
Leadership
- Todd Edwards, Chief Commercial Officer
- Joana Goncalves, Chief Medical Officer
- Arjun Agarwal, Senior Vice President Finance
- Rajiv Panwar, Vice President, CMC
- Iman Fayed, Controller
- Joana Goncalves, Chief Medical Officer
- Lawrence Klein, Chief Executive Officer
Verified email and direct lines for Oruka Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Oruka Therapeutics files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Oruka Therapeutics in the news
- ARCA biopharma and Oruka Therapeutics Announce Merger Agreement - GlobeNewswire (Apr 03, 2024)
- Paragon Therapeutics Announces Oruka Therapeutics Has Entered into Merger Agreement with ARCA biopharma to Advance Novel Treatments for Chronic Skin Diseases - PR Newswire (Apr 03, 2024)
- ARCA Biopharma and Oruka Therapeutics Agree to Merger - Dermatology Times (Apr 03, 2024)
- ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split - Yahoo Finance (Aug 29, 2024)
- Oruka spins out of Paragon with 3 assets, reverse merger and cash - Fierce Biotech (Apr 03, 2024)
- ARCA biopharma and Oruka Therapeutics announce merger - Investing.com UK (Apr 03, 2024)
Companies similar to Oruka Therapeutics
- ADARx Pharmaceuticals, Inc. · Biotechnology, Healthcare, Health Care, Therapeutics
- Enliven Therapeutics · Biotechnology, Healthcare, Health Care, Therapeutics
- Avalon Globocare Corp. · Biotechnology, Healthcare, Health Care, Therapeutics
- EyePoint Pharmaceuticals, Inc. · Biotechnology, Healthcare, Health Care, Therapeutics
- Olema Pharmaceuticals, Inc. · Biotechnology, Healthcare, Health Care, Therapeutics
About Oruka Therapeutics: questions and answers
What does Oruka Therapeutics do?
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka's mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as one or twice a year. Oruka is advancing a pr
Where is Oruka Therapeutics headquartered?
Oruka Therapeutics is headquartered in Menlo Park, California, United States.
Has Oruka Therapeutics raised funding?
Yes. Fundz has recorded 2 funding events for Oruka Therapeutics. The most recent, Post-IPO Equity of $200.0M, was in Sep 2024.
Who leads Oruka Therapeutics?
Arjun Agarwal is a Senior Vice President Finance at Oruka Therapeutics.
What is the latest news on Oruka Therapeutics?
On Aug 24, 2026, Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
Is Oruka Therapeutics a public company?
Yes. Oruka Therapeutics is publicly traded under the ticker ORKA.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy